mortality/aging
|
• 50% of mice die by 52 weeks; survival is increased relative to MRL-Faslpr mice
|
renal/urinary system
|
• not significantly different from Faslpr, Irf1-null mice or Faslpr, Irf1-sufficient mice
|
|
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes
|
hematopoietic system
|
• mice display similar T cell population profiles to Faslpr, Irf1-null mice
|
immune system
| N |
• TNF alpha production is not significantly different Faslpr, Irf1-sufficient mice or Faslpr, Irf1-null mice
|
|
• mice display similar T cell population profiles to Faslpr, Irf1-null mice
|
|
• at 26 weeks of age, levels are significantly higher relative to Faslpr, Irf1-null mice
|
|
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes
|
homeostasis/metabolism
|
• not significantly different from Faslpr, Irf1-null mice or Faslpr, Irf1-sufficient mice
|
integument
|
• mice display varying severity of skin irritation ranging from little or none to mild or moderate to severe
|


Analysis Tools